Comparative Pharmacology
Head-to-head clinical analysis: LIPITOR versus PRAVACHOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIPITOR versus PRAVACHOL.
LIPITOR vs PRAVACHOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to increased hepatic LDL receptor expression and reduced plasma LDL cholesterol.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to increased hepatic LDL receptor expression and reduced plasma LDL cholesterol.
Atorvastatin 10-80 mg orally once daily; initial dose 10-20 mg; titrate at 2-4 week intervals based on LDL-C response.
10-80 mg orally once daily, with or without food, typically in the evening.
None Documented
None Documented
14 hours; prolonged in hepatic impairment
The terminal elimination half-life of pravastatin is approximately 1.8 hours, but clinical LDL-cholesterol lowering effects persist beyond this due to sustained HMG-CoA reductase inhibition.
Biliary/fecal (90%); renal (10% as metabolites)
Approximately 70% of an oral dose is excreted in feces, primarily as metabolites, with about 20% recovered in urine. Biliary excretion is a major route for parent drug and metabolites.
Category C
Category C
HMG-CoA Reductase Inhibitor
HMG-CoA Reductase Inhibitor